PT-141 (Bremelanotide): Complete Guide to Sexual Wellness Peptide

What Is PT-141 (Bremelanotide)?

PT-141 is the development name for bremelanotide, a synthetic cyclic peptide. Its prescription form, Vyleesi, is an on-demand treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That means distressing low desire that developed after previously normal desire and is not limited to one situation or partner.

The indication excludes low desire explained by a medical or psychiatric condition, relationship problems, or medication effects. It is not a general sexual-performance enhancer. Research vials and nasal sprays bearing the PT-141 name are not the approved Vyleesi autoinjector. Vyleesi prescribing information.

Vyleesi was approved in 2019, but it was not the first systemic HSDD medicine: flibanserin (Addyi) was approved in 2015. original 2015 Addyi label.

How PT-141 Works: The Melanocortin Pathway

Established pharmacology: bremelanotide activates several melanocortin receptor subtypes, not MC4 alone. MC1 and MC4 binding are most relevant at therapeutic exposure. MC4-expressing neurons occur throughout the central nervous system; MC1 activity in pigment-producing cells helps explain skin darkening.

Proposed mechanism: preclinical work supports a role for melanocortin signaling in sexual motivation. However, the precise mechanism by which Vyleesi improves HSDD is unknown. A receptor model does not prove that it switches desire on, intensifies sensation, or works regardless of vascular health. Vyleesi prescribing information, section 12.1.

FDA Approval and Vyleesi: What This Means

The approval rests on two 24-week randomized, placebo-controlled RECONNECT trials in premenopausal women with acquired, generalized HSDD. They found improved desire scores and reduced distress compared with placebo. The number of satisfying sexual events, a key secondary endpoint, did not significantly improve. Kingsberg and colleagues: RECONNECT trials.

The approved product delivers a fixed 1.75 mg in 0.3 mL under the skin. It is not approved for men or postmenopausal women, or for medication-induced sexual dysfunction. Male research is worth discussing, but it is a separate evidence base—not an extension of the approved indication. Vyleesi prescribing information.

PT-141 vs Viagra and Cialis: Key Differences

These medicines address different diagnosed problems. A comparison is more useful when it separates desire, erectile function, route, and the population actually studied.

Mechanism of Action

Sildenafil and tadalafil inhibit PDE5, supporting the nitric-oxide/cGMP pathway involved in penile blood flow during sexual stimulation. They are not direct libido treatments. Viagra prescribing information; Cialis prescribing information.

Bremelanotide is a melanocortin receptor agonist with central nervous-system activity, but its clinical HSDD mechanism is not fully established. Different mechanisms do not establish superiority or make combinations automatically suitable.

When Each Works Best

Viagra and Cialis are established prescription options for erectile dysfunction in men. Vyleesi is an option for eligible premenopausal women with acquired, generalized HSDD. Neither diagnosis can be inferred simply from a report of low libido.

Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. Its central action does not make it a workaround for vascular disease or for someone unable to use a PDE5 inhibitor. It is also not the only medicine approved for HSDD; Addyi predates it. Vyleesi prescribing information; original 2015 Addyi label.

Side Effect Profiles

Viagra and Cialis can cause headache, flushing and indigestion; their labels include nitrate and riociguat contraindications and warnings about prolonged erections and sudden vision or hearing changes. Viagra prescribing information; Cialis prescribing information.

Vyleesi commonly causes nausea, flushing, injection-site reactions and headache. It can raise blood pressure temporarily and cause focal skin or gum darkening that may persist. These are product-specific profiles, not evidence that one drug is universally safer. Vyleesi prescribing information.

Timing and Flexibility

Viagra is generally taken about one hour before activity; its labeled window is 30 minutes to four hours beforehand. Cialis has as-needed and once-daily regimens, and as-needed benefit has been demonstrated up to 36 hours. This does not mean a continuous erection. Viagra prescribing information; Cialis prescribing information.

Vyleesi is taken at least 45 minutes beforehand. Its optimal administration window and duration of benefit after a dose have not been fully characterized. A fixed three-to-four-hour effect cannot be promised. Vyleesi prescribing information.

PT-141 Dosing Protocols and Administration

Vyleesi: one single-use autoinjector delivers 1.75 mg/0.3 mL subcutaneously into the abdomen or thigh, at least 45 minutes before anticipated activity. The device is fixed-dose; there is no labeled 0.75-to-1.25 mg titration or adjustable pen setting.

Do not administer more than one dose within 24 hours. More than eight doses per month is not recommended. This is a limit, not a target frequency. The label advises discontinuation after eight weeks if symptoms have not improved. Vyleesi prescribing information, section 2.

Research and individualized prescribing: early trials explored other doses and routes. That does not establish a self-directed starter, daily, twice-daily or nasal schedule. A prescribed compounded preparation needs its own concentration, device and handling instructions; a research-vendor vial is not interchangeable with Vyleesi.

Effects on Libido, Arousal, and Sexual Function

Desire, arousal, orgasm and distress are related but distinct outcomes. The strongest evidence concerns desire and related distress in the studied HSDD population; reports about other experiences need separate interpretation.

Increased Libido and Sexual Desire

The randomized trials support a benefit for some women with HSDD: desire scores improved more than with placebo. A positive average result does not mean everyone responds or that every dose creates desire. The trial-results section below explains the measured endpoints and response definition. Kingsberg and colleagues: RECONNECT trials.

Enhanced Arousal and Genital Sensation

Emerging and reported experience: accounts of greater arousal or sensitivity are relevant to how people experience treatment, but they are not reliable incidence estimates. Some secondary trial measures favored bremelanotide; after the key satisfying-event endpoint was not significant, remaining ranked secondary outcomes were exploratory. They should not be presented as definitive proof of increased genital sensation. Kingsberg and colleagues: RECONNECT trials.

Effects on Orgasm Quality

Reports of easier or more intense orgasms should be understood as individual experience, not an established effect for every user. The pivotal endpoints were desire and distress—not a guarantee of orgasm intensity. Changes in overall sexual-function questionnaires cannot be treated as proof of a specific neural pleasure mechanism.

Important Note on Individual Variability

Some people find treatment useful and others do not. Placebo responses were substantial, and tolerability can affect whether someone continues. Differences in response do not establish a genetic MC4-receptor explanation. Relationship context, mental health, medications and physical health also matter; those factors deserve attention rather than automatic dose escalation.

Side Effects and Safety Considerations

Most trial adverse events were mild or moderate, but side effects led some participants to stop. The rates below refer to the approved subcutaneous product in its trial population—not all PT-141 preparations or all users. Vyleesi prescribing information.

Nausea (Most Common)

Nausea affected 40% of Vyleesi-treated participants versus 1.3% on placebo in the pivotal trials; 8% of treated participants stopped because of it. It often improved after the first dose, but could recur. Persistent or severe nausea warrants a discussion about treatment or discontinuation—not a promise that tolerance will develop.

Routine ondansetron pretreatment is not recommended: a randomized study in the current label found it did not reduce nausea incidence. That differs from clinician-directed treatment of nausea after it occurs. Do not split a fixed-dose autoinjector to improvise a lower dose. Vyleesi prescribing information, sections 5.3 and 6.1.

Flushing and Facial Redness

Flushing occurred in 20.3% of Vyleesi-treated participants versus 0.3% with placebo. It is a recognized side effect, not proof that the desired effect has started. The trial data do not support a universal 10-to-30-minute duration or a promise that it becomes negligible with repeated use. Vyleesi prescribing information.

Blood Pressure Elevation

The label describes temporary blood-pressure increases and heart-rate reductions after dosing. Reported maximal trial increases were 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after a dose; values usually returned to baseline within 12 hours. These study findings are not an individual maximum or assurance of cardiovascular suitability.

Blood pressure should be controlled and cardiovascular risk assessed before treatment and periodically afterward. Known cardiovascular disease or uncontrolled hypertension are contraindications; high cardiovascular risk also weighs against use. Vyleesi prescribing information, section 5.1.

Pigmentation Changes and Melanoma Risk

Focal hyperpigmentation of areas such as the face, gums or breasts occurred in 1% of participants receiving up to eight monthly doses; risk was higher with daily exposure and in darker skin. Resolution was not confirmed in every affected participant. This is an observed warning, not merely theoretical. Vyleesi prescribing information, section 5.2.

The label does not list melanoma history as a formal contraindication or establish that bremelanotide causes melanoma. That does not make a changing mole harmless: new or changing pigmented lesions deserve medical assessment rather than an assumption that they are just a drug effect.

Headache and Other Effects

Headache occurred in 11.3%, injection-site reactions in 13.2%, and vomiting in 4.8% of Vyleesi-treated trial participants. Dizziness and fatigue were also reported. Rates from these trials should not be transferred to nasal sprays or unverified vials. Vyleesi prescribing information, section 6.1.

Contraindications and When to Avoid PT-141

Do not use Vyleesi with uncontrolled hypertension or known cardiovascular disease. It is not recommended for people at high cardiovascular risk. Severe kidney or liver impairment requires particular caution. Vyleesi prescribing information.

Use effective contraception during treatment and discontinue Vyleesi if pregnancy is suspected. Breastfeeding data are absent, so the label calls for an individualized discussion of maternal need and potential infant effects—not an established universal breastfeeding prohibition.

Medication review is important: delayed stomach emptying can alter oral drug absorption. Avoid combination with oral naltrexone-containing products used for alcohol or opioid addiction because reduced exposure can undermine treatment. Do not stop an existing medicine on your own to make room for PT-141. Vyleesi prescribing information, sections 7 and 8.

Clinical Trial Data and Efficacy Evidence

Read the primary research alongside the product label. They answer different questions: what happened under trial conditions, what remains uncertain, and how the approved product is intended to be used.

The RECONNECT Studies

Kingsberg and colleagues reported two 24-week double-blind trials—not eight-week trials. They randomized 1,267 women; 1,247 received treatment and formed the safety population, while 1,202 formed the modified intention-to-treat efficacy population.

The coprimary measures were the Female Sexual Function Index desire domain (FSFI-D) and item 13 of the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO), which assesses distress about low desire. Palatin sponsored the trials and participated in design, execution, analysis and reporting. Kingsberg and colleagues: RECONNECT trials.

Key Trial Results

Both coprimary endpoints favored bremelanotide. On a separate patient-perceived-benefit anchor (General Assessment Questionnaire question 3), response rates were 58.3% versus 36.1% in study 301 and 58.2% versus 35.4% in study 302. These are responses on that specific measure, not cure rates or the percentage achieving better orgasms. The key number-of-satisfying-events endpoint did not significantly improve. Kingsberg and colleagues: RECONNECT trials.

An optional 52-week open-label extension reported sustained improvements among participants, but had no placebo comparison during that period: 684 enrolled and 272 completed it. Selection and attrition limit generalization. It does not establish increasing MC4 sensitivity, safe daily use, or freedom from tolerance. Simon and colleagues: extension study.

A later Spielmans and Ellefson methodological reanalysis questioned outcome measures and the magnitude of benefit. That critique should be considered alongside the original positive findings, rather than presenting either universal success or no possible benefit.

Real-World Efficacy Beyond Trials

Individual reports: experiences ranging from substantial benefit to little change can inform questions to ask a clinician, but do not supply a reliable success rate or prove why someone responds.

Early male research: a placebo-controlled intranasal study found an erectile response in healthy men and men with erectile dysfunction, and reported generally favorable short-term tolerability. A separate small crossover study found that adding intranasal PT-141 enhanced the response to low-dose sildenafil. These are genuine research signals, not proof that Vyleesi is superior to Viagra or a validated male injection protocol. Diamond and colleagues: early intranasal study; 19-man crossover study.

PT-141 Compared to Other Treatments

The useful question is which problem is being treated. Low desire, erectile difficulty, medication effects and distress can overlap, but do not have interchangeable treatments.

PT-141 vs GLP-1 Agonists for Sexual Dysfunction

Semaglutide and tirzepatide treat metabolic conditions under their product-specific indications; they are not substitutes for an HSDD medicine. Reports of sexual changes during weight treatment may reflect multiple influences. Without a suitable direct comparison, they do not establish that a GLP-1 drug improves sexual function or that PT-141 is the better option for someone seeking weight management.

PT-141 vs SSRI Augmentation Strategies

Medication-associated sexual difficulties deserve review with the prescribing clinician. Vyleesi's indication specifically excludes low desire caused by medication, and the pivotal trials excluded antidepressant use. Therefore those trials do not establish it as an SSRI antidote or demonstrate an interaction-free combination. Do not reduce, switch or stop an antidepressant without the prescriber. Vyleesi prescribing information; Kingsberg and colleagues: RECONNECT trials.

PT-141 vs Testosterone Replacement

Testosterone treatment and bremelanotide are different clinical questions. A hormone diagnosis cannot be inferred from low desire alone, and the Vyleesi trials do not establish added benefit from combining the two. Ask the clinician to identify the relevant diagnosis, supporting evidence and monitoring for each proposed treatment instead of assuming that different mechanisms add up to better results.

PT-141 vs Psychotherapy

When relationship or psychological factors contribute, discussion with a qualified therapist or sexual-health clinician may help address those concerns. Vyleesi is not indicated for low desire explained by relationship problems or a psychiatric condition. An individualized combination of approaches may be reasonable, but a claim that PT-141 plus therapy is usually optimal needs direct evidence. Vyleesi prescribing information.

Access, Cost, and Availability

Vyleesi requires a prescription. As checked September 9, 2026, the manufacturer's access page advertises a four-dose box for $99 without coverage and potential $0 access for eligible commercially insured patients. These are program offers, not a universal monthly cost or insurance guarantee. Eligibility restrictions apply, including exclusions for government-funded coverage; confirm the current terms and any consultation cost before ordering.

Licensed compounding is not the same as a research-chemical vendor. Compounded medicines are not FDA-approved or automatically interchangeable with the brand; FDA describes the separate compounding framework and its role in meeting particular patient needs. The prescription, pharmacy, formulation, concentration and handling directions matter. A research-only label does not establish suitability for human use. Vyleesi approval alone does not establish that any particular compounded offering is legally available or clinically appropriate.